A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.

被引:0
|
作者
Ricciuti, Biagio [1 ]
Arbour, Kathryn C. [2 ]
Mahadevan, Navin R. [3 ]
Alessi, Joao V. [1 ]
Lindsay, James [1 ]
Umeton, Renato [1 ]
Sinha, Rileen [1 ]
Hoojghan, Amir [1 ]
Vokes, Natalie [1 ]
Recondo, Gonzalo [1 ]
Lamberti, Giuseppe [1 ]
Polio, Andrew [1 ]
Rizvi, Hira [2 ]
Leonardi, Giulia [1 ]
Plodkowski, Andrew J. [2 ]
Felt, Kristen [1 ]
Sharma, Bijaya [1 ]
Tolstorukov, Michael Y. [1 ]
Janne, Pasi A. [1 ]
Van Allen, Eliezer M. [1 ]
Sholl, Lynette M. [3 ]
Rodig, Scott J. [3 ]
Hellmann, Matthew D. [2 ]
Awad, Mark M. [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
490
引用
收藏
页数:2
相关论文
共 50 条
  • [31] PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
    Baek, M-H.
    Chen, L.
    Jelinic, P.
    Cristescu, R.
    Jin, X. Y.
    Shao, C.
    Tekin, C.
    Park, J-Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S758 - S758
  • [32] Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.
    Gibney, Geoffrey Thomas
    Tang, Shaojun
    Poorman, Kelsey
    Olszanski, Anthony J.
    Eisenberg, Burton Larry
    Mehmi, Inderjit
    Farma, Jeffrey M.
    In, Gino Kim
    Amin, Asim
    Rapisuwon, Suthee
    Vanderwalde, Ari M.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers
    Adashek, Jacob J.
    Kato, Shumei
    Pabla, Sarabjot
    Nesline, Mary
    Conroy, Jeffrey M.
    Subbiah, Vivek
    DePietro, Paul
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    Kloten, Vera
    Lampignano, Rita
    Krahn, Thomas
    Schlange, Thomas
    CELLS, 2019, 8 (08)
  • [35] Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
    Ma, Yuhui
    Li, Quan
    Du, Yaxi
    Chen, Wanlin
    Zhao, Guangqiang
    Liu, Xing
    Ye, Lianhua
    Li, Hongsheng
    Wang, Xiaoxiong
    Liu, Junxi
    Shen, Zhenghai
    Ma, Luyao
    Zhou, Yongchun
    ONCOTARGETS AND THERAPY, 2020, 13 : 5191 - 5198
  • [36] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [37] PD-L1 expression in different molecular subgroups of endometrial carcinomas
    Evsei, A.
    Birceanu, A.
    Copca, N.
    Dumitru, A.
    Sajin, M.
    VIRCHOWS ARCHIV, 2020, 477 : S63 - S63
  • [38] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [39] Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)
    Davis, Andrew A.
    Chae, Young Kwang
    Agte, Sarita
    Pan, Alan
    Mohindra, Nisha
    Villaflor, Victoria
    Raparia, Kirtee
    Giles, Francis J.
    CANCER RESEARCH, 2017, 77
  • [40] Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Suzuki, Takuji
    Ohe, Yuichiro
    LUNG CANCER, 2024, 191